A detailed history of National Bank Of Canada transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, National Bank Of Canada holds 1,000 shares of AVXL stock, worth $8,630. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$8,630
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.11 - $7.04 $92,475 - $158,400
-22,500 Reduced 95.74%
1,000 $5,000
Q1 2024

May 13, 2024

BUY
$4.55 - $6.75 $102,315 - $151,787
22,487 Added 2219.84%
23,500 $119,000
Q2 2023

Jul 26, 2023

SELL
$7.66 - $9.5 $2,681 - $3,325
-350 Reduced 25.68%
1,013 $8,000
Q4 2022

Jan 24, 2023

SELL
$7.65 - $14.43 $169,546 - $319,812
-22,163 Reduced 94.21%
1,363 $0
Q4 2021

Jan 24, 2022

BUY
$16.88 - $23.31 $397,118 - $548,391
23,526 New
23,526 $408,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.